<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00988364</url>
  </required_header>
  <id_info>
    <org_study_id>Merck-123</org_study_id>
    <secondary_id>MK0653A</secondary_id>
    <nct_id>NCT00988364</nct_id>
  </id_info>
  <brief_title>Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.</brief_title>
  <official_title>Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 in Patients With Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:

        -  To identify the common factor for L5 prevalence in patients with Metabolic Syndrome.

        -  To determine whether Ezetimibe, Simvastatin, and Vytorin can correct the L5- promoting
           factor and reduce L5 in Metabolic Syndrome patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epidemiological evidence indicates that metabolic syndrome (MS) is a strong predisposing
      condition for atherosclerosis. Elevation of plasma low-density lipoprotein (LDL)
      cholesterol(LDL-C) concentration is the most important risk factor for atherosclerosis;
      however, LDL-C elevation is not a criterion for metabolic syndrome, raising the question of
      LDL's role in the syndrome's association with atherosclerosis. L5, a highly electronegative
      and mildly oxidized LDL subfraction that we recently isolated from hypercholesterolemic human
      plasma, may provide a key to answering this question. In cultured vascular endothelial cells
      (EC), L5 inhibits proliferation and induces apoptosis and monocyte-EC adhesion. In our
      preliminary studies, L5 could also be detected in patients with MS without elevated LDL-C.
      Because other LDL subfractions were harmless to EC, the presence of MS-L5 prompted us to
      hypothesize that the atherogenic role of LDL is not solely determined by plasma LDL-C
      concentration, but more importantly, by its composition. The proposed study is designed to
      test this hypothesis. The first question we will address is what lipid factor determines the
      prevalence of L5 in MS.

      Subsequently, we will examine whether treatment with selected medicines can effectively
      reduce L5 in MS patients by correcting the factor favorable for L5 formation.

      We are in the process of identifying the active components of L5 to fully characterize the
      atherogenic role of L5 in MS,. In the current proposal, we focus our interest on the efficacy
      of Ezetimibe, Simvastatin, and Vytorin in reducing L5 from the plasma of MS patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">July 2010</completion_date>
  <primary_completion_date type="Anticipated">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To identify the common factor for L5 prevalence in Metabolic Syndrome patients.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine whether Ezetimibe, Simvastatin, and Vytorin can correct the L5- promoting factor and reduce L5 in Metabolic Syndrome.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Ezetimibe</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomly chosen participants will receive ezetimibe 10mg daily for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomly chosen participants will receive Simvastatin 20mg daily for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vytorin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomly chosen participants will receive Vytorin 20/10mg daily for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Randomly chosen participants will receive Placebo tab 1 daily for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Simvastatin 20mg daily for 3 months.</description>
    <arm_group_label>Simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vytorin</intervention_name>
    <description>Vytorin 20/10mg daily for 3 months.</description>
    <arm_group_label>Vytorin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo one tablet daily times 3 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>Ezetimibe 10mg daily for 3 months.</description>
    <arm_group_label>Ezetimibe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants who meet 3 or more of the 5 criteria specified in the ATPIII guidelines
             will be recruited.

          -  The 5 criteria are:

               1. abdominal obesity (men&gt;40 inches, women &gt;35 inches);

               2. TG&gt; 150mg/dL;

               3. low HDL-C (men &lt; 40mg/dL, women &lt; 50 mg/dL);

               4. high blood pressure (&gt;or=130/&gt;or=85 mmHg);

               5. fasting glucose &gt; or = 110mg/dL.

          -  People with different ethnic backgrounds will be included.

        Exclusion Criteria:

          -  symptomatic coronary artery disease

          -  peripheral vascular disease

          -  cerebral ischemia (stroke)

          -  smoking

          -  hypothyroidism

          -  kidney diseases

          -  consumption of antioxidation supplements/drugs or use of lipid-lowering drugs in the
             last 3 months

          -  women who are pregnant, nursing, or planning to become pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chu-Huang Chen, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christie Ballantyne, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah L Liscum, MPH</last_name>
    <phone>713-798-6476</phone>
    <email>slliscum@bcm.tmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Avogaro P, Cazzolato G, Bittolo-Bon G. Some questions concerning a small, more electronegative LDL circulating in human plasma. Atherosclerosis. 1991 Nov;91(1-2):163-71.</citation>
    <PMID>1811552</PMID>
  </reference>
  <reference>
    <citation>Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, Veltri EP; Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003 May 20;107(19):2409-15. Epub 2003 Apr 28.</citation>
    <PMID>12719279</PMID>
  </reference>
  <reference>
    <citation>Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004 Feb 24;109(7):837-42. Epub 2004 Feb 2.</citation>
    <PMID>14757686</PMID>
  </reference>
  <reference>
    <citation>Chan DC, Watts GF, Barrett PH, Mamo JC, Redgrave TG. Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity. Clin Chem. 2002 Feb;48(2):278-83.</citation>
    <PMID>11805008</PMID>
  </reference>
  <reference>
    <citation>Chen CH, Jiang T, Yang JH, Jiang W, Lu J, Marathe GK, Pownall HJ, Ballantyne CM, McIntyre TM, Henry PD, Yang CY. Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation. 2003 Apr 29;107(16):2102-8. Epub 2003 Apr 14.</citation>
    <PMID>12695302</PMID>
  </reference>
  <reference>
    <citation>Chen CH, Pace PW, Karakoc ND, Lu J, Chen HH, Henry PD, Pownall HJ Foreyt JP, Ballantyne CM, Yang CY. Effective reduction of novel atherogenic LDL subfraction by atorvastatin in patients with hypercholesteremia. J AM Coll Cardiol. 2004:43(suppl A):486A (Abstract)</citation>
  </reference>
  <reference>
    <citation>Chappey B, Myara I, Benoit MO, Mazière C, Mazière JC, Moatti N. Characteristics of ten charge-differing subfractions isolated from human native low-density lipoproteins (LDL). No evidence of peroxidative modifications. Biochim Biophys Acta. 1995 Dec 7;1259(3):261-70.</citation>
    <PMID>8541333</PMID>
  </reference>
  <reference>
    <citation>De Castellarnau C, Sánchez-Quesada JL, Benítez S, Rosa R, Caveda L, Vila L, Ordóñez-Llanos J. Electronegative LDL from normolipemic subjects induces IL-8 and monocyte chemotactic protein secretion by human endothelial cells. Arterioscler Thromb Vasc Biol. 2000 Oct;20(10):2281-7.</citation>
    <PMID>11031216</PMID>
  </reference>
  <reference>
    <citation>Demuth K, Myara I, Chappey B, Vedie B, Pech-Amsellem MA, Haberland ME, Moatti N. A cytotoxic electronegative LDL subfraction is present in human plasma. Arterioscler Thromb Vasc Biol. 1996 Jun;16(6):773-83.</citation>
    <PMID>8640405</PMID>
  </reference>
  <reference>
    <citation>Kleinman Y, Krul ES, Burnes M, Aronson W, Pfleger B, Schonfeld G. Lipolysis of LDL with phospholipase A2 alters the expression of selected apoB-100 epitopes and the interaction of LDL with cells. J Lipid Res. 1988 Jun;29(6):729-43.</citation>
    <PMID>2459282</PMID>
  </reference>
  <reference>
    <citation>La Belle M, Blanche PJ, Krauss RM. Charge properties of low density lipoprotein subclasses. J Lipid Res. 1997 Apr;38(4):690-700.</citation>
    <PMID>9144084</PMID>
  </reference>
  <reference>
    <citation>Lee SJ, Campos H, Moye LA, Sacks FM. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol. 2003 May 1;23(5):853-8. Epub 2003 Mar 13.</citation>
    <PMID>12637336</PMID>
  </reference>
  <reference>
    <citation>Libby P. Inflammation in atherosclerosis. Nature. 2002 Dec 19-26;420(6917):868-74. Review.</citation>
    <PMID>12490960</PMID>
  </reference>
  <reference>
    <citation>Sánchez-Quesada JL, Benítez S, Ordóñez-Llanos J. Electronegative low-density lipoprotein. Curr Opin Lipidol. 2004 Jun;15(3):329-35. Review.</citation>
    <PMID>15166790</PMID>
  </reference>
  <reference>
    <citation>Sevanian A, Bittolo-Bon G, Cazzolato G, Hodis H, Hwang J, Zamburlini A, Maiorino M, Ursini F. LDL- is a lipid hydroperoxide-enriched circulating lipoprotein. J Lipid Res. 1997 Mar;38(3):419-28.</citation>
    <PMID>9101423</PMID>
  </reference>
  <reference>
    <citation>Steinberg D. Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. Circulation. 1997 Feb 18;95(4):1062-71. Review.</citation>
    <PMID>9054771</PMID>
  </reference>
  <reference>
    <citation>Simons L, Tonkon M, Masana L, Maccubbin D, Shah A, Lee M, Gumbiner B. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Curr Med Res Opin. 2004 Sep;20(9):1437-45.</citation>
    <PMID>15383192</PMID>
  </reference>
  <reference>
    <citation>van Heek M, Austin TM, Farley C, Cook JA, Tetzloff GG, Davis HR. Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters. Diabetes. 2001 Jun;50(6):1330-5.</citation>
    <PMID>11375333</PMID>
  </reference>
  <reference>
    <citation>Yang CY, Raya JL, Chen HH, Chen CH, Abe Y, Pownall HJ, Taylor AA, Smith CV. Isolation, characterization, and functional assessment of oxidatively modified subfractions of circulating low-density lipoproteins. Arterioscler Thromb Vasc Biol. 2003 Jun 1;23(6):1083-90. Epub 2003 Apr 10.</citation>
    <PMID>12689919</PMID>
  </reference>
  <reference>
    <citation>Yang CY, Chen HH, Huang MT, Raya JL, Yang JH, Chen CH, Gaubatz JW, Pownall HJ, Taylor AA, Ballantyne CM, Jenniskens FA, Smith CV. Pro-apoptotic low-density lipoprotein subfractions in type II diabetes. Atherosclerosis. 2007 Aug;193(2):283-91. Epub 2006 Oct 9.</citation>
    <PMID>17030034</PMID>
  </reference>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2009</study_first_submitted>
  <study_first_submitted_qc>October 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2009</study_first_posted>
  <last_update_submitted>October 5, 2009</last_update_submitted>
  <last_update_submitted_qc>October 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Chu-Huang Chen, M.D., Ph.D.</name_title>
    <organization>Baylor College of Medicine</organization>
  </responsible_party>
  <keyword>Metabolic Syndrome</keyword>
  <keyword>LDL subfraction L5</keyword>
  <keyword>The reduction of LDL Chol in patients with Metabolic Syndrome</keyword>
  <keyword>The prevalence of L5 in patients with Metabolic Syndrome</keyword>
  <keyword>The reduction of L5 subfraction in patients with Metabolic Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

